News & Presentations

Umoja Biopharma Breaks Ground on Extensive Manufacturing Facility for its Next-Generation CAR T Immunotherapies
August 30, 2021

Seattle, Wash., August 30, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the groundbreaking of its new development and manufacturing facility in Louisville, Colo. Construction of the state-of-the-art facility is a key milestone for the company and represents an important next step in bringing effective and accessible CAR T therapies to cancer patients.

READ MORE >

Umoja Biopharma Appoints Greg Sargen to its Board of Directors
August 24, 2021

Seattle, Wash., August 24, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointment of Greg Sargen to its Board of Directors.

READ MORE >

Umoja Biopharma Expands Management Team with Key Hires in Research and Business Development
July 27, 2021

Seattle, Wash., July 27, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointments of three new hires in the company’s research and business development functions, including Bruce Kerwin, Ph.D. as Senior Vice President of Process and Product Development, Ryan Larson, Ph.D. as Vice President and Head of Translational Science, and Mike Fitzpatrick as Vice President of Business Development and Operations.

READ MORE >

Umoja Biopharma Closes an Oversubscribed $210 Million Series B Financing to Expand Integrated Immunotherapy Platforms and Advance Programs to the Clinic
June 15, 2021

Seattle, Wash., June 15, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the completion of an oversubscribed $210 million Series B financing.

READ MORE >

Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer
June 8, 2021

Seattle, WA, June 8, 2021– Umoja Biopharma, a leading oncology company leveraging its proprietary, integrated technologies to reprogram immune cells directly in the human body to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer.

READ MORE >

We are led by a world class team that operates on a foundation of respect for the contributions of everyone on the Umoja team.